Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial-processing peptidase subunit alpha (PMPCA) is the alpha subunit of mitochondrial processing peptidase (MPP), a heterodimeric enzyme located in the mitochondrial matrix that is essential for cleaving the N-terminal transit peptides from nuclear-encoded mitochondrial precursor proteins, thereby enabling their proper folding, import, and maturation[1][2][4]. It forms a functional heterodimer with the beta subunit (PMPCB), which contains the catalytic site, while PMPCA is necessary for substrate recognition and binding[1][2]. Deficiency or mutation in PMPCA impairs mitochondrial protein processing, and is causally linked to a range of neurodegenerative diseases, including autosomal recessive spinocerebellar ataxia and Friedreich ataxia, as well as late-onset dominant optic atrophy[3][4]. PMPCA’s activity is indispensable for cellular viability, especially neuronal health, and altering its function can cause severe mitochondrial dysfunction and neurodegeneration[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial-processing peptidase subunit alpha (PMPCA).